Navigation Links
Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
Date:4/1/2008

tein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA.

About Monogram

Monogram is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the demand for our testing products, including our Trofile Assay, the potential use of our Trofile Assay for patient selection for the class of HIV drugs known as CCR5 antagonists, the size and timing of Progenics' clinical trials utilizing our products, the outlook for Progenics' investigational drug mentioned in this release and for our testing products, expected protection provided by patents, possible regulation of our products by the FDA. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for CCR5 antagonists or other HIV drugs; whether larger confirmatory clinical studies will confirm the results of initial studies;
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium
2. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
3. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... PRINCETON, N.J., Feb. 2, 2011 Eli Lilly and ... Company (NYSE: BMY ) announced today that ... global Phase III studies evaluating necitumumab, an investigational anti-cancer ... lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO) ...
... BOTHELL, Wash., Feb. 2, 2011 Cardiac Science Corporation ... ) and diagnostic cardiac monitoring devices, has been ... Flow Control facilities globally. Tyco Flow Control is a $3.4B ... facilities throughout the globe. The first phase of the rollout, ...
Cached Medicine Technology:Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 3Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 4Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 5Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 6Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 7Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 8Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 9Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 10Tyco Division Awards Global AED Contract to Cardiac Science 2Tyco Division Awards Global AED Contract to Cardiac Science 3Tyco Division Awards Global AED Contract to Cardiac Science 4
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... has announced plans to release a newly redesigned website at Healthpointe.net. The new ... enhanced user experience. , The redesign serves to provide smoother interactions between ...
(Date:7/31/2015)... ... July 31, 2015 , ... ZH Healthcare announces a ... , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare dedicated ... a service (SaaS). , HITaaS manages all aspects of infrastructure, security, ...
(Date:7/31/2015)... ... July 31, 2015 , ... EB ... and Hospital Medicine Practice, is pleased to announce that it has partnered with ... format available on iPhones, iPads, and Android smartphones and tablets. , “The ...
(Date:7/31/2015)... ... ... The Radiology Business Management Association’s 2015 Fall Educational Conference ... Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, Tex. ... has a special understanding of the real world impact of health care policy issues,” ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3
... new vaccine called the TAT vaccine has been developed in ... date. And more importantly it has had a 71% success ... for human testing and this may be the brightest hope ... of the Department of Virology at Italy’s National Health Institute ...
... social neglect and being unwanted even by near and dear ... like the other people - wherever they want and whenever ... passengers. Others are just indifferent. Leaving the ethical issues aside, ... of, many reasons. Primarily the physicians of these patients do ...
... The outgoing U.S. president Bill Clinton will be remembered as ... by becoming the first American president in history to be ... to win at the senate did he save himself and ... of many burning controversies throughout his term and his mid ...
... pregnancy can lead to increased risk of heart problems ... environment contribute to several aspects of cardiovascular risks in ... ,People whose mothers starved during the first 13 ... their adult life, Starvation during mid or late pregnancy ...
... cancer is pancreatic cancer, though it isn’t very common. Globally ... is some hope for the unfortunate victims. A new vaccine ... it has increased the survival rates in many. ,Vaccines ... In cancer, however, they are used along with other therapies ...
... new research into how our immunity works says stress reduces ... long we have agreed that stress is bad for our ... is sure to cause a lot of concern. , ... claming many victims every day, the new buzzword is immunity ...
Cached Medicine News:
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: